ETC-1002, A MODULATOR OF ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AND ADENOSINE TRIPHOSPHATE-CITRATE LYASE, WAS SAFE AND REDUCED LOW-DENSITY LIPOPROTEIN-CHOLESTEROL IN HEALTHY VOLUNTEERS

Methods Multiple ascending doses of ETC-1002 were evaluated in 56 healthy subjects, some with mildly elevated low density lipoprotein-cholesterol (LDL-C; >100 mg/dL), in two Phase 1, randomized, double-blind (sponsor open), placebo (PBO)-controlled studies.

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 61; no. 10; p. E1463
Main Authors MacDougall, Diane, Vanderlugt, James, Rosenberg, Noah, DiCarlo, Lorenzo, Milad, Mark, Margulies, Janice, Newton, Roger
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 12.03.2013
Elsevier Limited
Subjects
Cardiology
Cardiovascular
Cholesterol
Kinases
Metabolism
Metabolites
Online AccessGet full text

Cover

More Information
Summary:Methods Multiple ascending doses of ETC-1002 were evaluated in 56 healthy subjects, some with mildly elevated low density lipoprotein-cholesterol (LDL-C; >100 mg/dL), in two Phase 1, randomized, double-blind (sponsor open), placebo (PBO)-controlled studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(13)61463-1